Vioxx Withdrawal: Leadership Failure at Merck and the FDA
This paper examines the 2004 withdrawal of rofecoxib (Vioxx) — characterized as the largest prescription drug withdrawal in history — as a case study in leadership failure. Drawing on trait theories of leadership from Northouse (2016) and Daft (2007), the paper argues that senior executives at Merck and leadership at the FDA demonstrated critical deficiencies in integrity, responsibility, and insight. Despite clear warning signs regarding cardiovascular risk, Merck prioritized commercial interests while the FDA failed its public health mandate. The analysis illustrates how the absence of core leadership traits can produce catastrophic consequences for public safety.
- Introduction: The Vioxx Withdrawal: Background on Vioxx recall and key actors
- Leadership Traits and the Standard of Accountability: Trait theory framework from Northouse and Daft
- Failure of Integrity and Responsibility at Merck: Merck's commercial priorities over patient safety
- The FDA's Failure of Public Health Mandate: FDA's neglect of regulatory duty and oversight
- Conclusion: Leadership failures as root cause of crisis
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Anchors its critique in established leadership trait theory, using Northouse (2016) and Daft (2007) to provide a clear evaluative framework rather than relying solely on opinion.
- Connects a high-profile real-world event directly to academic concepts, making the argument both concrete and theoretically grounded.
- Identifies specific failures — lack of integrity, responsibility, and insight — and maps each to the actions of distinct actors (Merck executives vs. FDA leadership), avoiding vague generalization.
Key academic technique demonstrated
The paper uses leadership trait theory as a diagnostic lens, applying a checklist of leadership qualities drawn from peer-reviewed sources to evaluate decision-makers in a case study. This technique — measuring real actors against an academic framework — is a core skill in applied leadership and organizational behavior courses.
Structure breakdown
The paper opens with factual context about the Vioxx withdrawal, establishing stakes and identifying the key actors. It then introduces the theoretical framework (trait-based leadership theory) before applying those traits critically to both Merck and the FDA. The conclusion is implicit within the analytical paragraph, tying commercial motivation and regulatory failure together as a unified leadership crisis. The structure is tight and appropriate for a short analytical essay.
Introduction: The Vioxx Withdrawal
In what has been described as the largest prescription drug withdrawal in history, Merck withdrew rofecoxib (Vioxx) on September 30, 2004, following what Topol (2004) identifies as an excessive risk of stroke and myocardial infarction associated with the drug. The withdrawal came despite an FDA approval five years earlier and $2.5 billion in sales. At the time of its withdrawal, the medication had been taken by approximately 80 million patients worldwide. Topol (2004) argues that this debacle could have been avoided had clear warning signs not been ignored along the way. The primary leaders implicated in this case were the senior executives at Merck and the leadership of the FDA.
Leadership Traits and the Standard of Accountability
The entire fiasco is representative of a colossal failure of leadership. Rodger Stodgill (as cited in Northouse, 2016) identifies key traits of effective leadership as including "persistence, insight, initiative, self-confidence, responsibility, cooperativeness, tolerance, influence, and sociability" (p. 21). Other essential traits, according to Daft (2007), include integrity, intelligence, and honesty. Leaders at both the FDA and Merck were found lacking in several of these traits — most critically in integrity, responsibility, and insight.
Failure of Integrity and Responsibility at Merck
Senior executives at Merck were blinded by the company's commercial interests and consequently ignored significant safety concerns. Rather than addressing documented cardiovascular risks, Merck directed its attention toward a public relations campaign designed to downplay adverse cardiovascular effects. This response demonstrates a clear lack of insight into the long-term consequences of prioritizing profit over patient safety. Sales were valued above safety — a choice that reveals a fundamental lack of integrity on the part of Merck's top leadership. The need to conduct a trial assessing the cardiovascular benefits and risks of rofecoxib and celecoxib was ignored throughout, despite the availability of evidence that warranted urgent investigation.
Conclusion
The Vioxx debacle stands as a cautionary example of what happens when core leadership traits — integrity, responsibility, and insight — are subordinated to commercial interest and institutional inertia. Both Merck and the FDA bore responsibility for a preventable public health crisis that harmed millions of patients. The case underscores the critical importance of ethical leadership in both corporate and regulatory environments, where decisions carry profound consequences for public safety.
References
Daft, R. (2007). The Leadership Experience (4th ed.). Mason, OH: Cengage Learning.
Northouse, P. G. (2016). Leadership: Theory and Practice (7th ed.). Washington, DC: SAGE Publications.
Topol, E. J. (2004). Failing the public health — Rofecoxib, Merck, and the FDA. New England Journal of Medicine, 351(17), 1707–1709.
Create your account
Always verify citation format against your institution’s current style guide requirements.